drugset

drugset / Trial / NCT06613360

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

NCT06613360 ↗

Phase 1 Recruiting 24 enrolled Cullinan Therapeutics Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Timeline

Start: 2025-01-21
Primary completion: 2026-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CLN-978	Other / unclassified	—	Subcutaneous

Indications